Mustafa Khasraw (find me in BlueSky)
@MKhasraw
Followers
808
Following
4K
Media
109
Statuses
1K
Oncologist @DukeU; interested in cancer research, clinical trials, immunotherapy but many other things - Views are my own
Planet Earth
Joined May 2019
Behind the scenes: Chelsea Railton, Kelly M. Hotchkiss and Kirit Singh @KiritSingh in the lab!
1
1
5
In glioma, T cell immunotherapies are limited by the quantity of available T cells. @KiritSingh @PeterFecci @MKhasraw & team address this challenge in preclinical models by peripheral injection of autologous T cells after pre-treatment with IL-7. Full report
2
11
39
Primary results of RELATIVITY-098 showing that adjuvant nivo+rela does not improve RFS over nivo alone, HR 1.01, biomarker data pointing to value of presence of tumor as a potential requirement for LAG3 blockade to improve efficacy. Neoadjuvant Nivo/rela had >60% MPR
2
8
26
Congrats @StephenBagleyMD @DrORourke2 and colleagues @PennCancer on their manuscript in @NatureMedicine showing safety and early efficacy of bivalent CAR T cells in 18 patients with recurrent #glioblastoma! https://t.co/n2QewBy7MZ
3
33
155
Honored to be recognized as the Pennsylvania Medical Society Top 40 under 40. Grateful for my patients, colleagues and mentors who inspire me daily to keep pushing for better answers. @SSMahaseMD
@PennStNeurosurg
@PennStateGME
#Cancer
https://t.co/8ucAhr1z3s
3
2
56
JCI - IL-7-mediated expansion of autologous lymphocytes increases CD8+ VLA-4 expression and accumulation in glioblastoma models https://t.co/LJsZ2PCi98
@KiritSingh
0
1
4
A Spatial Multi-Omic Framework Identifies Gliomas Permissive to TIL Expansion
biorxiv.org
Tumor-infiltrating lymphocyte (TIL) therapy, recently approved by the FDA for melanoma, is an emerging modality for cell-based immunotherapy. However, its application in immunologically “cold” tumors...
2
3
23
It's a huge honor to be a part of this truly remarkable set of speakers at the Stand Up for Science rally tomorrow in DC in front of the Lincoln Memorial! (My first speech at this kind of an event!)
37
55
551
Check out our latest article in Neuro-Oncology, wherein we outline challenges, lessons learned, and even resources (including protocols) for anyone interested in liquid biopsy studies. "Hitchhiker’s Guide Toward CSF Biomarkers for Neuro-Oncology" @JeffreyZuccato @MKhasraw
1
3
28
Infiltrating plasma cells maintain glioblastoma stem cells through IgG-Tumor binding: Cancer Cell
0
3
15
Honored & humbled
We are proud to announce our 4th DSA recipient of 2024, Zhao Zhang, Ph.D. from @Duke_PCB! His project is titled 'Targeting Genomic Parasites for Glioblastoma Immunotherapy.' #TheSontagFoundation #DSA2024 #DSAGrantee @zz_zhaozhang
7
2
69
Anonymous donor gives $50 million to Duke for a proton beam therapy center #protonbeamtherapy
https://t.co/juWO3Nsb78
neurosurgery.duke.edu
An anonymous donor has made a $50 million gift to Duke University Health System toward the development of a proton beam therapy center. The donation is the largest philanthropic gift received by Duke...
1
8
32
Delighted to share our comprehensive review on leptomeningeal disease now online @NatRevClinOncol Items covered: 1. Distinct pathogenesis of LMD and how it varies from parenchymal brain metastases 2. How cancer cells metabolically in the CSF and evade immune cells 3. Latest
4
24
103
🚨🥁🥁🥁 Hot off the press! @NatRevClinOncol 🚨 Leptomeningeal Metastatic Disease: New Frontiers and Future Directions - Discover groundbreaking insights into LMD in our latest review. ✅From novel diagnostics to cutting-edge therapies like intrathecal and immunotherapies, we
Delighted to share our comprehensive review on leptomeningeal disease now online @NatRevClinOncol Items covered: 1. Distinct pathogenesis of LMD and how it varies from parenchymal brain metastases 2. How cancer cells metabolically in the CSF and evade immune cells 3. Latest
3
9
32
We are thrilled to announce that GCAR has executed an agreement with @AstraZeneca for the evaluation of AstraZeneca’s compound, AZD1390, in GBM AGILE, the world’s first global adaptive platform trial for patients with #glioblastoma. The AZD1390 arm will be evaluated for the
1
3
14
Such an interesting story on systemic T cell response inhibition presented by Alexandra Hoyt-Miggelbrik from the @KAyasoufi Lab @Dukeneurosurg #SNO2024
1
1
21
“Team science is what’s going to move us forward, it’s what drives discovery,” said Dr. Mitchel S. Berger of @NeurosurgUCSF and ABTA board member, during his acceptance speech of the @NeuroOnc Lifetime Achievement Award. Thank you, Mitch, for your leadership! 🏆
Congratulations to Mitchel Berger for receiving the Lifetime Achievement Award. #SNO2024 #ScientificMeeting
1
4
18